Atlas Trials

Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

Clinical trial NCT05398861 · RECRUITING

Trial details

NCT number
NCT05398861
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER-2 Negative Breast Cancer
Start date
2022-08-19
Primary completion
2026-12-30
Enrollment
79

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.